In this periodic feature, PharmAsia News Bureau Chief Vikas Dandekar provides his latest analysis on the India pharma industry courtesy of CNBC-TV 18 Mumbai.
In this interview, Vikas decodes one of the biggest mysteries this year to hit the pharma world: Why did Ranbaxy team up with Teva on generic Lipitor (atorvastatin), and what are the terms of that relationship?
Continue reading "CNBC Interviews PharmAsia News: Ranbaxy-Teva Lipitor Deal Decoded" »
The pharmaceutical and life sciences landscape is changing fast in China. There are close to 1,000 bio-related companies in China, and half were established in the last five years or so. Citi expects China’s pharmaceutical market to grow from its current level of $40 billion to $100 billion by 2015 and to $200 billion by 2020, which will make it the second largest in the world, passing Japan along the way.
Continue reading "China: The New Land of Opportunity for Biopharma Companies? " »
Article preview from "PharmAsia News"- August 30, 2011
NEW DELHI - As part of a comprehensive overhaul, India's Department of Ayush, which deals with the Indian traditional system of medicine, locally known as ayurveda, has decided to close 180 ayurveda-based medical colleges that have not been operating according to prescribed standards.
Continue reading "India Moves To Close Traditional Medicine Colleges Not Operating According To Standards " »
The massive earthquake and tsunami that hit Japan on March 11th has so far resulted in almost 15,000 lives lost and more than 13,000 people are still missing. More than 77,000 houses/buildings were completely destroyed and so many people still live in uncertainty. Our thoughts and prayers remain with those who have suffered in this tragic natural disaster.
In response to the disaster in Japan, New York Pharma Forum will hold a fundraiser, co-hosted by the Consulate-General of Japan in New York, on Wednesday, June 1st, 5:30-8:00 pm, at the Consul General's formal residence in Manhattan.
Continue reading "Japan Fundraiser Hosted By New York Pharma Forum" »
Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.
Continue reading "Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 1 of 2) " »
In this periodic feature, PharmAsia News Bureau Chief Vikas Dandekar provides his latest analysis on the India pharma industry courtesy of CNBC-TV 18 Mumbai.
Continue reading "CNBC Interviews PharmAsia News: Cipla tells Merck your anti-AIDS drug too costly in India" »
